IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Reader Login
Users Online : 329 
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission


Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2004| July-August  | Volume 36 | Issue 4  
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Neonatal streptozotocin-induced rat model of Type 2 diabetes mellitus: A glance
DK Arulmozhi, A Veeranjaneyulu, SL Bodhankar
July-August 2004, 36(4):217-221
Diabetes mellitus is a group of syndromes characterized by hyperglycemia, altered metabolism of lipids, carbohydrates and protein and an increased risk of complication of vascular diseases. Type 2 diabetes mellitus is characterized by derangement of insulin secretion and an inability of the peripheral tissues to respond to insulin. In spite of the availability of many animal models for Type 2 diabetes mellitus including genetic and chemically induced, none of them simulate human Type 2 diabetes mellitus. An attempt has been made in the present review, to evaluate the neonatal streptozotocin-induced rat (n-STZ rats) model of Type 2 diabetes mellitus, for its potential advantages as a suitable model over the others. The n-STZ model (with alteration of dose and day of STZ injection) exhibits various stages of Type 2 diabetes mellitus such as impaired glucose tolerance, and mild, moderate and severe glycemia. The cells in n-STZ rats bear a resemblance to insulin secretory characteristics found in patients with Type 2 diabetes mellitus. Thus the n-STZ model can be considered as one of the suitable animal models of Type 2 diabetes mellitus.
  42,547 2,542 31
Acute and chronic effects of aspirin on hematological parameters and hepatic ferritin expression in mice
MA Merchant, Deepak N Modi
July-August 2004, 36(4):226-230
OBJECTIVE: To examine the acute and chronic effects of aspirin on peripheral blood and bone marrow counts and hepatic ferritin expression in mice. MATERIAL AND METHODS: Adult male albino mice were orally administered aspirin at a dose of 600 mg/kg thrice daily for 7 days or 150 mg/kg once daily for 6/7 days up to 25 weeks. At the end of the experiment the red and white blood cell counts, hemoglobin, and packed cell volume were estimated. Bone marrow films were studied to estimate the rate of erythropoiesis and leucopoiesis. Expression of liver ferritin was tested by immunohistochemistry. RESULTS: Acute or chronic doses of aspirin reduced the RBC count, hemoglobin and other red cell indices as compared to controls. The WBC counts were higher in the treated animals as compared to the untreated animals. Both the treatment regimens appeared to suppress the rate of erythropoiesis in the marrow, while the rate of leucopoiesis appeared to increase in the marrow of the treated animals. Aspirin treatment did not significantly affect the expression of ferritin in the liver. CONCLUSION: Aspirin in either acute or chronic doses induces anemia associated with leucocytosis in mice; the anemia does not seem to be induced due to alterations in iron metabolism. The drug appears to use multiple targets which affect red cell production and maturation processes.
  39,717 299 2
Clinical trials in India: Pangs of globalization
Arun Bhatt
July-August 2004, 36(4):207-208
  28,807 1,450 7
Hypoglycemic activity of Ficus hispida (bark) in normal and diabetic albino rats
Rajib Ghosh, Kh Sharatchandra, S Rita, IS Thokchom
July-August 2004, 36(4):222-225
OBJECTIVE: To find out the hypoglycemic activity of Ficus hispida Linn. (bark) in normal and diabetic albino rats and to evaluate its probable mechanism of hypoglycemic activity if any. MATERIAL AND METHODS: Albino rats were divided into groups (n=6) receiving different treatments consisting of vehicle, water-soluble portion of the ethanol extract of Ficus hispida bark (FH) (1.25 g/kg) and standard antidiabetic drugs, glibenclamide (0.5 mg/kg) and 0.24 units of insulin (0.62 ml of 0.40 units/ml). Blood glucose was estimated by the glucose oxidase method in both normal and alloxan-induced diabetic rats before and 2 h after the administration of drugs. To find out the probable mechanism of action of FH as a hypoglycemic agent, i) the glycogen content of the liver, skeletal muscle and cardiac muscle, and ii) glucose uptake by isolated rat hemi-diaphragm were estimated. RESULTS: FH showed significant reduction of blood glucose level both in the normal (P<0.01) and diabetic (P<0.001) rats. However, the reduction in the blood glucose level was less than that of the standard drug, glibenclamide. FH also increased the uptake of glucose by rat hemi-diaphragm significantly (P<0.001). There was a significant increase in the glycogen content of the liver (P<0.05), skeletal muscle (P<0.01) and cardiac muscle (P<0.001). The amount of glycogen present in the cardiac muscle was more than the glycogen present in the skeletal muscle and liver. CONCLUSION: FH has significant hypoglycemic activity. Increased glycogenesis and enhanced peripheral uptake of glucose are the probable mechanisms involved in its hypoglycemic activity.
  20,850 1,155 23
Is nimesulide safe in a cardiovascular-Compromised patient?
SZ Rahman, RA Khan
July-August 2004, 36(4):252-253
  15,533 270 2
A validated high-performance liquid chromatography method for the determination of rifampicin and desacetyl rifampicin in plasma and urine
AK Hemanth Kumar, I Chandra, R Geetha, KS Chelvi, V Lalitha, G Prema
July-August 2004, 36(4):231-233
OBJECTIVE: To standardize a high-performance liquid chromatography (HPLC) method for the determination of rifampicin (RMP) and its major metabolite desacetyl rifampicin (DRMP) in plasma and urine. MATERIAL AND METHODS: A simple, specific and sensitive HPLC method was developed for the determination of RMP and DRMP in plasma and urine. Separation in both was achieved by reverse-phase chromatography on a C18 column with a mobile phase composition of 0.05 M phosphate buffer: acetonitrile (55:45 v/v) at 254 nm. RESULTS: The retention times of DRMP, RMP and Rifapentine (RPN), the internal standard were 2.9, 4.8 and 10.5 min respectively. The assay was linear from 0.25 to 15.0 g ml-1 for plasma and 2.5 to 80.0 g ml-1 for urine. Both intra-day and inter-day accuracy and precision data showed good reproducibility. CONCLUSION: The HPLC method described is sensitive, selective and linear for the wide range of concentrations for RMP and DRMP in plasma and urine. Thus, the method developed is well suited for the pharmacokinetic studies.
  11,386 502 9
The hypoglycemic activity of Coccinia indica Wight & Arn. and its influence on certain biochemical parameters
SP Dhanabal, CK Koate, M Ramanathan, K Elango, B Suresh
July-August 2004, 36(4):249-250
  10,692 393 2
A case of losartan-induced dry irritating cough
Vishal Tandon, B Kapoor, V Chopra, A Mahajan, BM Gupta
July-August 2004, 36(4):251-251
  9,805 148 -
Hepatotoxicity of isoniazid: A study on the activity of marker enzymes of liver toxicity in serum and liver tissue of rabbits
S Karthikeyan
July-August 2004, 36(4):247-249
  6,956 351 2
L-arginine-nitric oxide pathway modulates morphine-induced inhibition of gall bladder emptying in mice
MP Basanagouda, N Khatib, ST Boreddy
July-August 2004, 36(4):262-264
  6,909 146 -
Cardio-respiratory effects of DRDE-07, a new prophylactic agent for sulphur mustard toxicity, in anesthetized rats
V Malviya, R Singh, D Kumar, U Pathak, P Kumar, DK Jaiswal, R Mathur, R Vijayaraghavan
July-August 2004, 36(4):234-237
OBJECTIVE: To study the cardio-respiratory effects of DRDE-07, a new prophylactic agent for sulphur mustard. MATERIAL AND METHODS: The effect of DRDE-07 was studied in anesthetized male rats (Wistar), by administering it either by intraperitoneal or oral routes. Different doses (0.25, 0.5, 1.0 and 2.0 LD50) were used and various cardio-respiratory parameters viz., mean arterial blood pressure, heart rate, respiratory rate and tidal volume were monitored on an oscillograph. RESULTS: Intraperitoneal administration of 0.5 and 1.0 LD50 and oral administration of 0.25 LD50 of DRDE-07 did not produce any effect on the cardio-respiratory variables. Oral administration of 0.5 and 1.0 LD50 showed a significant decrease in mean arterial blood pressure after 60 min. None of the animals died in the two-hour monitoring period. Two (2.0) LD50 administration of DRDE-07 either by intraperitoneal or oral routes induced a sudden decrease in the mean arterial blood pressure and the animals died within one hour. CONCLUSION: DRDE-07 did not show any significant effect on the cardio-respiratory variables at a dose of 0.25 LD50 by oral route and 1.0 LD50 by intraperitoneal route. The death after intraperitoneal or oral administration (2.0 LD50) of DRDE-07 is due to the sudden fall in the mean arterial blood pressure.
  6,663 161 2
Morphological and biochemical basis of centchroman as a novel antineoplastic agent in MCF-7 human breast cancer cells
S Srivastava, R Sharma, Anil K Balapure
July-August 2004, 36(4):238-243
OBJECTIVE: To investigate the antineoplastic potential of a novel antiestrogen (AE) centchroman (CENT) using cell morphology, viability and cathepsin-D (Cath-D) gene expression as indices in MCF-7 human breast cancer cell line. MATERIAL AND METHODS: MCF-7 cells were incubated with CENT (1 ÁM, 10 ÁM) in the absence and presence of 17- estradiol (E2, 10 nM) for 4 days. Investigations were carried out on alterations in cell morphology, number, Cath-D gene expression using Phase Contrast Microscopy, Trypan-blue dye exclusion and spectrophotometric assay. A standard antiestrogen and antibreast cancer agent tamoxifen (TAM -1 ÁM, 10 ÁM) was used as a positive control. RESULTS: E2 (10 nM) alone significantly up-regulated the cells morphologically, numerically and biochemically thus establishing their hormonal responsiveness. TAM and CENT at 1 ÁM each enhanced and reduced the viable cell number respectively whereas both elevated the Cath-D activity. However, 35mm photographic evidence did not indicate any cytotoxic effect with either drug as compared to control. Addition of E2 to the two ligands separately affected the three parameters similar to that in E2 alone. With 10 ÁM TAM and CENT individually, the cells were visually devastated and so were the viable cell numbers and Cath-D gene expression. Supplementation of E2 under similar conditions failed to undo the damage to the cells morphologically and quantitatively. However, disparate results were observed with regards to the enzyme activity where TAM+E2 caused inhibition and CENT+E2 resulted in an induction. CONCLUSION: It can be concluded that both the AEs TAM and CENT displayed similarities in their antineoplastic action on MCF-7 cells as observed by morphological and viability studies except that the latter proved cytotoxic even at 1ÁM concentration. TAM and CENT showed a similar effect on Cath-D gene expression except at the higher dose (10 ÁM). These results suggest that the antiestrogen CENT has better antineoplastic potential as opposed to TAM.
  6,420 232 9
Antiplasmodial activity of seven plants used in African folk medicine
G Bidla, V PK Titanji, B Joko, G El Ghazali, A Bolad, K Berzins
July-August 2004, 36(4):245-246
  6,393 222 7
Piracetam attenuates minoxidil-induced antinociception in mice
Ashish K Rehni, D Rehni
July-August 2004, 36(4):246-247
  6,418 165 1
Bioequivalence: An overview of statistical concepts
Shubha Rani, A Pargal
July-August 2004, 36(4):209-216
Bioequivalence (BE) means the absence of a greater-than-allowable difference between the systemic bioavailability of a test product and that of a reference product. Studies to test the BE of drug products, and the statistical basis for their design, analysis and interpretation, have evolved over the last two decades. A crossover design is preferred over a parallel-group design as it segregates the inter-subject variation (which is not product-dependent) from the intra-subject variation (which is product-dependent). The value of testing two one-sided null hypotheses of non-equivalence at a significance level of 0.05, and the importance of estimating a 90% confidence interval of the ratio (test/reference) of mean AUC and Cmax values, and of the difference between mean Tmax values, are now recognized and form the current standards for BE. The number of subjects required for a BE study with the desired power (at least 0.80) and significance level (0.05), depends on the expected deviation of the test product from the reference product and the error variance associated with the bioavailability parameters (AUC, Cmax, Tmax etc.) of the drug substance. At present, according to the Indian regulatory authority, the number of subjects required to conduct a BE study is 12 which is inadequate for most drug substances by the current international standards and criteria. This review expounds the foregoing principles of BE testing.
[ABSTRACT]   Full text not available  [PDF] [CITATIONS]
  5,628 863 6
Towards a more meaningful teaching of pharmacology
VS Mathur
July-August 2004, 36(4):259-261
  6,159 220 2
A novel therapeutic approach in rheumatoid arthritis
S Rashmi, Ujala Verma
July-August 2004, 36(4):265-266
  5,451 328 1
Newer dopamine-serotonin system stabilising atypical antipsychotic agent: Aripiprazole
SP Dutta, T Sharma, DC Dhasmana, KC Mishra, RK Kaul
July-August 2004, 36(4):267-267
  5,505 268 -
Anti TNF- therapy in congestive heart failure
Shalini Gupta, CD Tripathi
July-August 2004, 36(4):257-258
  5,330 196 -
A case report of celecoxib-induced generalized edema and hypertension
S Chattopadhyay, R Chatterjee
July-August 2004, 36(4):254-255
  5,016 161 -
Pharmacological investigation of prunin-6"-O-p-coumarate: A flavonoid glycoside
D Harikrishna, A VN Appa Rao, MC Prabhakar
July-August 2004, 36(4):244-245
  4,772 211 -
Centers for disease control and prevention
Jatinder Singh
July-August 2004, 36(4):268-269
  4,218 123 -
Bibliography management with EndNote 7.0
Girish Venkataraman, V Ananthanarayanan
July-August 2004, 36(4):257-257
  4,108 129 -
Selective cyclooxygenase-2 inhibitors in inflammatory bowel disease
SK Kulkarni, VP Singh
July-August 2004, 36(4):256-256
  4,019 207 -
A budding pharmacologist left us
VM Motghare
July-August 2004, 36(4):272-272
  3,140 107 -
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow